
Kate A Dolan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7108514/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Social and structural determinants of health associated with drug use patterns among female sex workers in Iran: A latent class analysis. International Journal of Drug Policy, 2021, 91, 102798.	3.3	5
2	Shining light on darkness: suicidal ideation and suicide attempt among Iranian women who do and do not use drugs. Drugs: Education, Prevention and Policy, 2021, 28, 349-356.	1.3	0
3	HIV/AIDS, hepatitis and tuberculosis-related mortality among incarcerated people: a global scoping review. International Journal of Prisoner Health, 2021, ahead-of-print, 66-82.	0.9	2
4	A randomised controlled trial of motivational interview for relapse prevention after release from smoke-free prisons in Australia. International Journal of Prisoner Health, 2021, 17, 462-476.	0.9	3
5	Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Eurosurveillance, 2021, 26, .	7.0	4
6	Health service provision for disease control among prisoners: a conceptual note. Journal of Health Research, 2020, 34, 353-358.	0.8	4
7	Availability, Accessibility, and Coverage of Needle and Syringe Programs in Prisons in the European Union. Epidemiologic Reviews, 2020, 42, 19-26.	3.5	17
8	Prisoners should not be left behind in HCV research and policies. Harm Reduction Journal, 2020, 17, 33.	3.2	8
9	Global Prison Health Care Governance and Health Equity: A Critical Lack of Evidence. American Journal of Public Health, 2020, 110, 303-308.	2.7	37
10	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
11	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. International Journal of Population Data Science, 2020, 5, 1145.	0.1	9
12	A Randomized Controlled Trial of Brief Cognitive Behavioral Therapy for Regular Methamphetamine Use in Methadone Treatment. Journal of Psychoactive Drugs, 2019, 51, 280-289.	1.7	13
13	Estimating the number of people who inject drugs and syringe coverage in Australia, 2005–2016. Drug and Alcohol Dependence, 2019, 197, 108-114.	3.2	20
14	National and sub-national HIV/AIDS-related mortality in Iran, 1990–2015: a population-based modeling study. International Journal of STD and AIDS, 2019, 30, 1362-1372.	1.1	1
15	Age-Specific Global Prevalence of Hepatitis B, Hepatitis C, HIV, and Tuberculosis Among Incarcerated People: A Systematic Review. Journal of Adolescent Health, 2018, 62, S18-S26.	2.5	27
16	HIV and Viral Hepatitis Among Imprisoned Key Populations. Epidemiologic Reviews, 2018, 40, 12-26.	3.5	42
17	Prevalence of Drug Injection, Sexual Activity, Tattooing, and Piercing Among Prison Inmates. Epidemiologic Reviews, 2018, 40, 58-69.	3.5	48
18	A managed alcohol program in Sydney, Australia: Acceptability, costâ€savings and nonâ€beverage alcohol use. Drug and Alcohol Review, 2018, 37, S184-S194.	2.1	20

#	Article	IF	CITATIONS
19	Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern. Asian Journal of Psychiatry, 2018, 31, 49-55.	2.0	18
20	Dynamic Models of Infectious Disease Transmission in Prisons and the General Population. Epidemiologic Reviews, 2018, 40, 40-57.	3.5	57
21	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
22	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
23	Brief intervention on Smoking, Nutrition, Alcohol and Physical (SNAP) inactivity for smoking relapse prevention after release from smoke-free prisons: a study protocol for a multicentre, investigator-blinded, randomised controlled trial. BMJ Open, 2018, 8, e021326.	1.9	5
24	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
25	Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. Epidemiologic Reviews, 2018, 40, 82-95.	3.5	49
26	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. BMJ Open, 2018, 8, e020723.	1.9	11
27	Veiled Truths: Iranian Women and Risky Sexual Behavior in the Context of Substance Use. Journal of Reproduction and Infertility, 2018, 19, 237-246.	1.0	4
28	A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug and Alcohol Review, 2017, 36, 305-310.	2.1	32
29	Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005â€2014: The <scp>HITS</scp> â€p study. Journal of Viral Hepatitis, 2017, 24, 733-741.	2.0	61
30	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. Harm Reduction Journal, 2017, 14, 19.	3.2	33
31	P4.109â€Narcotics are cheaper than food in pakistan: our pwids are dying from aids. , 2017, , .		0
32	Trends in cancer incidence and survival for Indigenous and nonâ€Indigenous people in the Northern Territory. Medical Journal of Australia, 2017, 207, 46-46.	1.7	1
33	Public health alternatives to incarceration for drug offenders. Eastern Mediterranean Health Journal, 2017, 23, 222-230.	0.8	10
34	Determinants of Consistent Condom Use Among Iranians Living with HIV/AIDS: Implication for Prevention. International Journal of High Risk Behaviors & Addiction, 2017, 6, .	0.2	5
35	Therapeutic Community Program for Opioid-Dependent Treatment Seekers. Iranian Journal of Psychiatry and Behavioral Sciences, 2017, 11, .	0.4	1
36	Opioid Use among Women on a Stable Methadone Dose. Iranian Journal of Psychiatry and Behavioral Sciences, 2017, 11, .	0.4	1

#	Article	IF	CITATIONS
37	Prisoners coâ€infected with tuberculosis and HIV: a systematic review. Journal of the International AIDS Society, 2016, 19, 20960.	3.0	20
38	Natural killer cells in highly exposed hepatitis Câ€seronegative injecting drug users. Journal of Viral Hepatitis, 2016, 23, 464-472.	2.0	3
39	Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007–2013. Journal of Substance Abuse Treatment, 2016, 70, 58-63.	2.8	2
40	Hepatitis Câ€specific effector and regulatory <scp>CD</scp> 4 Tâ€cell responses are associated with the outcomes of primary infection. Journal of Viral Hepatitis, 2016, 23, 985-993.	2.0	13
41	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet, The, 2016, 388, 1228-1248.	13.7	213
42	Views of Iranian prison staff towards needle-exchange program in prison. Drugs: Education, Prevention and Policy, 2016, 23, 113-119.	1.3	3
43	Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet, The, 2016, 388, 1089-1102.	13.7	458
44	Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet, The, 2016, 388, 1115-1126.	13.7	157
45	HIV, prisoners, and human rights. Lancet, The, 2016, 388, 1202-1214.	13.7	72
46	Women-only drug treatment services and needs in Iran: the first review of current literature. DARU, Journal of Pharmaceutical Sciences, 2016, 24, 3.	2.0	16
47	Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. PLoS ONE, 2016, 11, e0150655.	2.5	15
48	HIV Responses in Arab States on the Southern Persian Gulf Border: The First Review. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, 10, e5392.	0.4	7
49	Comparison of Characteristics of Methamphetamine Versus Opiate Users in Tehran, Iran. International Journal of High Risk Behaviors & Addiction, 2016, 5, .	0.2	1
50	Methamphetamine Use Disorder Untreated among Women in Methadone Treatment in Iran. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, In Press, .	0.4	2
51	Methamphetamine Use Disorder Untreated among Women in Methadone Treatment in Iran. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, In Press, .	0.4	0
52	Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment. Addiction and Health, 2016, 8, 90-97.	0.2	7
53	The development and evaluation of stimulant treatment programmes. Current Opinion in Psychiatry, 2015, 28, 280-285.	6.3	1
54	Compulsory treatment of drug users in Asia: designed to torture?. International Journal of Prisoner Health, 2015, 11, 255-268.	0.9	3

#	Article	IF	CITATIONS
55	Substance Use and HIV Among Female Sex Workers and Female Prisoners. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, S110-S117.	2.1	103
56	Transmitted/Founder Viruses Rapidly Escape from CD8 ⁺ T Cell Responses in Acute Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5478-5490.	3.4	31
57	Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country. Asian Journal of Psychiatry, 2015, 16, 17-25.	2.0	59
58	HIV and Hepatitis C Virus Infection and Risk Behaviors Among Heterosexual, Bisexual, and Lesbian Women Who Inject Drugs in Australia. LGBT Health, 2015, 2, 127-134.	3.4	10
59	Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian Journal of Psychiatry, 2015, 16, 78-83.	2.0	64
60	Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies. International Journal of Prisoner Health, 2015, 11, 30-38.	0.9	5
61	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012. Emerging Infectious Diseases, 2015, 21, 765-774.	4.3	37
62	Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 2015, 26, 976-983.	3.3	44
63	People who inject drugs in prison: HIV prevalence, transmission and prevention. International Journal of Drug Policy, 2015, 26, S12-S15.	3.3	71
64	Detection of drugs in Australian prisons: supply reduction strategies. International Journal of Prisoner Health, 2014, 10, 111-117.	0.9	5
65	A prospective study of hepatitis <scp>C</scp> incidence in Australian prisoners. Addiction, 2014, 109, 1695-1706.	3.3	58
66	Opioid use, treatment and harm reduction services: the first report from the Persian Gulf region. Journal of Substance Use, 2014, , 1-7.	0.7	15
67	Per-Event Probability of Hepatitis C Infection during Sharing of Injecting Equipment. PLoS ONE, 2014, 9, e100749.	2.5	14
68	Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence. Substance Abuse and Rehabilitation, 2012, 3, 37.	4.8	23
69	Effect of prisonâ€based opioid substitution treatment and postâ€release retention in treatment on risk of reâ€incarceration. Addiction, 2012, 107, 372-380.	3.3	89
70	Effect of pegylated interferonâ€î±â€2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 957-965.	2.8	38
71	Maternal and neonatal complications of substance abuse in Iranian pregnant women. Acta Medica Iranica, 2012, 50, 411-6.	0.8	20
72	Characteristics of Iranian Women Seeking Drug Treatment. Journal of Women's Health, 2011, 20, 1687-1691.	3.3	35

#	Article	IF	CITATIONS
73	The establishment of a methadone treatment clinic for women in Tehran, Iran. Journal of Public Health Policy, 2011, 32, 219-230.	2.0	25
74	Incidence and risk for acute hepatitis C infection during imprisonment in Australia. European Journal of Epidemiology, 2010, 25, 143-148.	5.7	74
75	Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health, 2010, 10, 633.	2.9	69
76	Compulsory detoxification is a major challenge to harm reduction in China. International Journal of Drug Policy, 2010, 21, 165-166.	3.3	13
77	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology, 2010, 52, 1216-1224.	7.3	156
78	A review of HIV in prisons in Nepal. Kathmandu University Medical Journal, 2010, 7, 351-354.	0.2	7
79	HIV in Indian prisons: risk behaviour, prevalence, prevention & treatment. Indian Journal of Medical Research, 2010, 132, 696-700.	1.0	6
80	A Literature Review of International Implementation of Opioid Substitution Treatment in Prisons: Equivalence of Care?. European Addiction Research, 2009, 15, 107-112.	2.4	64
81	Examining HIV, drug use and risk behaviours: A case study in the custodial settings of Thailand and Indonesia. International Journal of Prisoner Health, 2009, 5, 180-191.	0.9	3
82	[Commentary] PRISON RESEARCH. Addiction, 2009, 104, 223-223.	3.3	4
83	Presence of hepatitis C virus in syringes confiscated in prisons in Australia. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1655-1657.	2.8	7
84	Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care. Australian and New Zealand Journal of Public Health, 2008, 32, 86-87.	1.8	7
85	Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 2008, 33, 1602-1605.	3.0	41
86	An exploratory study of needlestick injuries among Australian prison officers. International Journal of Prisoner Health, 2008, 4, 164-168.	0.9	8
87	An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research and Theory, 2008, 16, 607-617.	1.9	10
88	HIV Testing Among Lesbian Women: Social Contexts and Subjective Meanings. Journal of Homosexuality, 2008, 54, 307-324.	2.0	1
89	Evaluation of a prisonâ€based naltrexone program. International Journal of Prisoner Health, 2007, 3, 214-224.	0.9	10
90	Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence, 2007, 91, 228-235.	3.2	117

#	Article	IF	CITATIONS
91	HIV in prison in low-income and middle-income countries. Lancet Infectious Diseases, The, 2007, 7, 32-41.	9.1	210
92	Shooting Gallery Operation in the Context of Establishing a Medically Supervised Injecting Center: Sydney, Australia. Journal of Urban Health, 2007, 84, 255-266.	3.6	26
93	Value for money in drug treatment: economic evaluation of prison methadone. Drug and Alcohol Dependence, 2006, 84, 160-166.	3.2	37
94	Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia, 2006, 17, 70-72.	1.2	9
95	Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduction Journal, 2006, 3, 2.	3.2	47
96	Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health, 2006, 14, 120-125.	1.5	52
97	Hair analysis underestimates heroin use in prisoners. Drug and Alcohol Review, 2006, 25, 425-431.	2.1	6
98	Survey of drug consumption rooms: service delivery and perceived public health and amenity impact. Drug and Alcohol Review, 2005, 24, 21-24.	2.1	55
99	Fourâ€year followâ€up of imprisoned male heroin users and methadone treatment: mortality, reâ€incarceration and hepatitis C infection. Addiction, 2005, 100, 820-828.	3.3	223
100	Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health, 2005, 4, 7.	3.5	1
101	Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduction Journal, 2005, 2, 2.	3.2	40
102	A review of HIV prevention among young injecting drug users: A guide for researchers. Harm Reduction Journal, 2005, 2, 5.	3.2	12
103	What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health, 2005, 4, 5.	3.5	11
104	Clearance of Hepatitis C Viremia Associated with Cellular Immunity in the Absence of Seroconversion in the Hepatitis C Incidence and Transmission in Prisons Study Cohort. Journal of Infectious Diseases, 2004, 189, 1846-1855.	4.0	147
105	Evaluation of the Condom Distribution Program in New South Wales Prisons, Australia. Journal of Law, Medicine and Ethics, 2004, 32, 124-128.	0.9	34
106	An overview of the use of urine, hair, sweat and saliva to detect drug use. Drug and Alcohol Review, 2004, 23, 213-217.	2.1	152
107	Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs?. Drug and Alcohol Review, 2004, 23, 281-286.	2.1	23
108	Risk Factors for Hepatitis C Infection and Perception of Antibody Status among Male Prison Inmates in the Hepatitis C Incidence and Transmission in Prisons Study Cohort, Australia. Journal of Urban Health, 2004, 81, 448-452.	3.6	21

#	Article	IF	CITATIONS
109	HIV education in a Siberian prison colony for drug dependent males. International Journal for Equity in Health, 2004, 3, 7.	3.5	23
110	Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison History, Hepatitis C Status and Drug Treatment Experiences. Journal of Ethnicity in Substance Abuse, 2004, 2, 51-58.	0.9	7
111	Drug consumption facilities: an update since 2000. Drug and Alcohol Review, 2003, 22, 227-233.	2.1	117
112	Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination?. Drug and Alcohol Review, 2003, 22, 317-321.	2.1	77
113	Decreased heroin availability in Sydney in early 2001. Addiction, 2003, 98, 93-95.	3.3	57
114	Prisonâ€based syringe exchange programmes: a review of international research and development. Addiction, 2003, 98, 153-158.	3.3	122
115	A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug and Alcohol Dependence, 2003, 72, 59-65.	3.2	169
116	Drug Use and Its Correlates in an Australian Prisoner Population. Addiction Research and Theory, 2003, 11, 89-101.	1.9	53
117	Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. International Journal of Epidemiology, 2003, 32, 717-724.	1.9	129
118	Hepatitis C transmission and HIV postâ€exposure prophylaxis after needleâ€Âand syringeâ€sharing in Australian prisons. Medical Journal of Australia, 2003, 178, 546-549.	1.7	35
119	Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. Medical Journal of Australia, 2001, 174, 183-184.	1.7	57
120	Can hepatitis C transmission be reduced in Australian prisons?. Medical Journal of Australia, 2001, 174, 378-379.	1.7	20
121	Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction, 2001, 96, 1289-1296.	3.3	81
122	Supporting needle and syringe programs in Australia. Australian and New Zealand Journal of Public Health, 2001, 25, 187-187.	1.8	2
123	Drug consumption facilities in Europe and the establishment of supervised injecting centres in Australia. Drug and Alcohol Review, 2000, 19, 337-346.	2.1	135
124	Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997. Medical Journal of Australia, 2000, 172, 57-61.	1.7	103
125	HIV transmission in a prison system in an Australian State. Medical Journal of Australia, 1999, 171, 14-17.	1.7	76
126	HIV risk behaviour and prevention in prison: a bleach programme for inmates in NSW. Drug and Alcohol Review, 1999, 18, 139-143.	2.1	16

#	Article	IF	CITATIONS
127	Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug and Alcohol Review, 1998, 17, 153-158.	2.1	75
128	A bleach program for inmates in NSW: an HIV prevention strategy. Australian and New Zealand Journal of Public Health, 1998, 22, 838-840.	1.8	26
129	A mathematical model of HIV transmission in NSW prisons. Drug and Alcohol Dependence, 1998, 50, 197-202.	3.2	16
130	Hepatitis B and C in New South Wales prisons: prevalence and risk factors. Medical Journal of Australia, 1997, 166, 127-130.	1.7	113
131	HIV prevalence and risk behaviour in needle exchange attenders: a national study. Medical Journal of Australia, 1997, 166, 237-240.	1.7	68
132	Hiv Risk Behaviour of Idus Before, During and After Imprisonment in New South Wales. Addiction Research, 1996, 4, 151-160.	0.6	42
133	8.5 HIV prevention in the community: injecting drug users. Medical Journal of Australia, 1996, 165, 266-267.	1.7	3
134	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 164, 508-508.	1.7	7
135	Is a syringe exchange feasible in a prison setting?. Medical Journal of Australia, 1996, 165, 59-59.	1.7	1
136	An International Review of Methadone Provision in Prisons. Addiction Research, 1996, 4, 85-97.	0.6	31
137	Is there a role for contact tracing in preventing HIV transmission among injecting drug users?. Addiction, 1996, 91, 917-919.	3.3	3
138	Methadone maintenance reduces injecting in prison. BMJ: British Medical Journal, 1996, 312, 1162-1162.	2.3	59
139	AIDS behind bars. Aids, 1995, 9, 825-832.	2.2	52
140	Evidence of HIV transmission in an Australian prison. Medical Journal of Australia, 1994, 160, 734-734.	1.7	25
141	Evidence of HIV transmission in an Australian prison. Medical Journal of Australia, 1994, 161, 509-509.	1.7	12
142	Reductions in HIV risk behaviour and stable HIV prevalence in syringe-exchange clients and other injectors in England. Drug and Alcohol Review, 1993, 12, 133-142.	2.1	10
143	HIV testing, and the care and treatment of HIV positive people in English prisons. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1993, 5, 199-206.	1.2	9
144	Life-style factors and social circumstances of syringe sharing in injecting drug users. Addiction, 1992, 87, 993-1003.	3.3	60

Kate A Dolan

#	Article	IF	CITATIONS
145	Drug Injecting and Syringe Sharing in Custody and in the Community: An Exploratory Survey of HIV Risk Behaviour. Howard Journal of Criminal Justice, 1990, 29, 177-186.	0.7	27
146	Sexual behaviour of injecting drug users and associated risks of HIV infection for Non-injecting sexual partners. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1989, 1, 51-58.	1.2	73
147	Changes in HIV risk behaviour in clients of syringe-exchange schemes in England and Scotland. Aids, 1989, 3, 267-272.	2.2	84
148	HIV Transmission Risk Behaviour of Clients Attending Syringe-exchange Schemes in England and Scotland. Addiction, 1988, 83, 1449-1455.	3.3	38
149	A Volatile Time for British Drug Policies: commentary on the Editorial by Alan Glanz. Addiction, 1988, 83, 1241-1242.	3.3	1
150	Syringe exchange schemes for drug users in England and Scotland. BMJ: British Medical Journal, 1988, 296, 1717-1719.	2.3	68
151	Antibodies to the human immunodeficiency virus in needles and syringes used by intravenous drug abusers. Medical Journal of Australia, 1987, 147, 275-276.	1.7	30